94 results
424B5
EYEN
Eyenovia Inc
9 Apr 24
Prospectus supplement for primary offering
7:11pm
delivery system, branded the Optejet® which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient … and other public health safety measures.
Management continues to closely monitor the impact of the COVID-19 pandemic on all aspects of the business
8-K
EX-99.1
EYEN
Eyenovia Inc
19 Mar 24
Regulation FD Disclosure
8:39am
dilation is desired. IMPORTANT SAFETY INFORMATION. CONTRAINDICATIONS: Known hypersensitivity to any component of the formulation. WARNINGS AND PRECAUTIONS … reduction Safety and tolerability with low incidence of IOP spikes Simplicity for patients with twice-a-day dosing Patented APNT Science Ease of Access
8-K/A
EX-99.1
EYEN
Eyenovia Inc
31 Jan 24
Regulation FD Disclosure
8:13am
SAFETY INFORMATION. CONTRAINDICATIONS: Known hypersensitivity to any component of the formulation. WARNINGS AND PRECAUTIONS. FOR TOPICAL OPHTHALMIC … provider Enhanced Safety Lower systemic exposure 1. Optometry and Vision Science94(6):638 - 646, June 2017 2. Int J Health Sci (Qassim). 2013 Nov;7(3
8-K
EX-99.1
alv0hkht p4d5xg
16 Jan 24
Eyenovia Re-Acquires Development and Commercialization Rights to MicroPine
8:24am
8-K
EX-99.2
69d73hr6olbf3xchz
13 Nov 23
Eyenovia Reports Third Quarter 2023 Financial Results and Provides Business Update
4:15pm
8-K
EX-99.1
w39pup7
13 Nov 23
Eyenovia Reports Third Quarter 2023 Financial Results and Provides Business Update
4:15pm
8-K
EX-99.1
9383sjo28ssg7
20 Sep 23
Regulation FD Disclosure
8:23am
424B5
ga2pu4x0ggvgy90tq0w
25 Aug 23
Prospectus supplement for primary offering
12:07pm
8-K
EX-99.2
csfzwgq
16 Aug 23
Eyenovia Acquires U.S. Commercial Rights to APP13007 (Clobetasol Propionate Ophthalmic Nanosuspension, 0.05%) from Formosa Pharmaceuticals
7:31am
8-K
fmk4xgwk 7ac
16 Aug 23
Eyenovia Acquires U.S. Commercial Rights to APP13007 (Clobetasol Propionate Ophthalmic Nanosuspension, 0.05%) from Formosa Pharmaceuticals
7:31am
8-K
EX-99.1
1g2u u4pky2t2447
16 Aug 23
Eyenovia Acquires U.S. Commercial Rights to APP13007 (Clobetasol Propionate Ophthalmic Nanosuspension, 0.05%) from Formosa Pharmaceuticals
7:31am
8-K
EX-99.1
7o201yni
10 Aug 23
Eyenovia Reports Second Quarter 2023 Financial Results and Provides Business Update
4:18pm
8-K
EX-99.1
0jhk5 2rlsnpgzg9h
27 Jun 23
Regulation FD Disclosure
9:00am
8-K
EX-99.2
ymw3s91gbo2tve krb
11 May 23
Eyenovia Reports First Quarter 2023 Financial Results and Provides Business Update
4:28pm